Worldwide rates of HSV infection - counting both cold sores (HSV-1) and herpes proper (HSV-2) - are between 65% and 90%. Although many people infected with HSV develop labial or genital lesions, the majority are either undiagnosed or display no physical symptoms-individuals with no symptoms are described as asymptomatic or as having subclinical herpes.
Herpes news. Read the latest research on the herpes virus, including new treatment options.
Genital herpes vaccine succeeds in mid-stage trial Agenus Inc said a trial of its experimental genital herpes vaccine reduced the rate at which patients released the virus, reducing the likelihood of infecting others, sending its shares up 32 percent in premarket trading.The 15 percent reduction in the release of the virus by patients receiving the vaccine in a mid-stage trial compared to those on a placebo, who showed no reduction.The vaccine, HerpV, also reduced the severity of the infection by 34 percent.The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months.
The history behind the creation of a vaccine against HPV, which causes cervical cancer, is fraught with blind alleys, delicate moments, humor and triumph. A third antiviral drug can suppress the lesions caused by genital herpes, according to a Canadian study published today. The drug, famciclovir, is manufactured by SmithKline Beecham, which financed the study.
Oct. 21, 2013 at 10:16 PM ET To confirm the theory that humans spread out from Africa tens of thousands of years ago, all you have to do is follow the cold sores. Or, to be more precise, follow the mutation patterns encoded in the genome of the virus that causes those cold sores.
